Detailed Description: |
Cas No. :7085-55-4
Product name |
trihydroxyethylrutin |
Alias |
Troxerutin; Trihydroxylrutin; 3',4',7-Tris[O-(2-hydroxyethyl)]rutin; 2-[3,4-bis(2-hydroxyethoxy)phenyl]-5-hydroxy-7-(2-hydroxyethoxy)-4-oxo-4H-chromen-3-yl 6-O-(6-deoxyhexopyranosyl)hexopyranoside; 2-[3,4-bis(2-hydroxyethoxy)phenyl]-5-hydroxy-7-(2-hydroxyethoxy)-4-oxo-4H-chromen-3-yl 6-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranoside; 2-[3,4-bis(2-hydroxyethoxy)phenyl]-5-hydroxy-7-(2-hydroxyethoxy)-4-oxo-4H-chromen-3-yl 6-O-(6-deoxy-alpha-L-mannopyranosyl)-D-glucopyranoside |
CAS RN |
7085-55-4 |
EINECS No. |
230-389-4 |
Molecular weight |
742.6752 |
Assay |
It is a mixture of Trihydroxyethylrutin (3 ', 4 ', 7 - Tris [O - (2 - hydroxyethyl)] rutin) as main ingredient. Based on anhydrous matter, the assay of Trihydroxyethylrutin (C33H42O19) is not less than 80.0% (for injection) and 60.0% (for oral use). |
Specifications |
WS-10001-(HD-0226)-2002 |
Upstream products |
rutin |
Packing |
25kg/drum |
Physicochemical properties |
yellow, yellow-green or light brown yellow powder; Odorless, salt taste;hygroscopicity, the product is soluble in water easily, slightly soluble in methanol, practically insoluble in ethanol and insoluble in chloroform. |
Uses |
Used as anticoagulant, can prevent thrombosis, is suitable for hemiplegia, aphasia and myocardial infarction, atherosclerosis caused by cerebral thrombosis and cerebral embolism. |
|